

Biomarker discovery research— Cancer molecular profiling

ABSTRACT

Research in the discovery and identification of new, targetable biomarkers is driven by comprehensive tumor profiling using next generation sequencing (NGS). However, converting tissue samples into NGS libraries is often challenging due to the low quantity and quality of DNA in such samples. Here, we present confident and accurate identification of low-frequency variants by combining the xGen™ cfDNA & FFPE DNA Library Prep Kit, optimized for low-input and degraded samples, with IDT xGen hybridization capture reagents.

This workflow features a proprietary single-stranded ligation strategy that maximizes conversion, effectively eliminates adapter-dimer formation, and reduces chimera rates. Since dimer formation is negligible, a fixed concentration of adapter can be used, and aggressive size selection is no longer required post-ligation. The xGen cfDNA & FFPE DNA Library Prep Kit yields high coverage and library complexity, enabling highly accurate identification of low-frequency variants. We demonstrate identifying tumor-associated variants in both matched formalin-fixed, paraffin-embedded (FFPE) and cell-free DNA (cfDNA) samples with a proof-of-concept experiment using archived lung cancer trio samples.

INTRODUCTION

Most cancers are associated with mutated genes. Gene mutations can be inherited or occur by environmental exposure. Some mutations can lead to cancer when triggered by viral exposure, while others can occur in regulatory elements that control gene expression. Studying genomics, genes, and gene function give researchers and clinicians insight into how mutated genes impact cancer symptoms, tumor progression, treatment response, and health outcomes. **The Cancer Genome Atlas (TCGA)** provides a comprehensive database that includes insight on the molecular characterization of various cancers, which deepens the understanding of cancer [1].

TCGA is a dataset compiled over a period of 12 years drawing from samples of over 1000 subjects. In addition to expanding our knowledge of cancer molecular and genomic mechanisms, TCGA has also revolutionized cancer classification by revealing the heterogeneity of molecular signatures, or biomarkers, of tumors between tissue types and individual patients. TCGA identified cancer subtypes and revealed how tumors can be targeted for treatment by exploiting biomarkers, paving the way toward personalized medicine.

Identifying new biomarkers can aid in personalizing medicine by targeting tumors for treatment. Biomarkers indicate a disease or outcome, often because they are involved in the biological mechanism. Variants, or mutations, in biomarker genes can impact disease risk, affect a subject's response to treatment, or lead to genetic dysregulation that results in disease. Molecular characterization of tumor types can identify biomarkers through comprehensive tumor profiling with NGS. When matched normal and tumor samples are compared, tumor-specific mutations and their functions can be identified. One way to compare samples is by using a biopsy, a sample of tissue or cells taken from the body. A liquid biopsy can be saliva, blood, or other bodily fluid.

> SEE WHAT MORE WE CAN DO FOR YOU AT WWW.IDTDNA.COM.

Blood-based tests are commonly used to monitor disease progression in retrospective studies and present an attractive alternative to traditional biopsies due to their noninvasive nature and the ease of collecting multiple samples over time.

The challenge with these approaches is that tumor sample DNA is often low quality and complex sample type for constructing NGS libraries. DNA can come from samples that are formalin-fixed and paraffin-embedded (FFPE) to preserve proteins and tissue structures, or it can be cell-free DNA (cfDNA), DNA obtained through liquid biopsy. cfDNA may represent tumors that cannot be biopsied or can be used to assess multiple tumors at once. However, using cfDNA for analysis is often limited by small amounts of material and very low proportions of tumor-derived DNA. Successful library conversion is paramount when working with these types of samples.

Why is conversion important?

Conversion is the transformation of input material into library molecules for NGS. When the library is prepared, genetic material is fragmented and ligated to adapters to prepare it for sequencing. The ability of a library prep kit or workflow to convert the input material into a sequenceable product is called the conversion rate. High conversion results in higher yields with fewer PCR cycles, lower bias, an increased confidence in identifying low-frequency mutations, and an NGS library that accurately represents the input sample. In contrast, low conversion yields lower library complexity (the number of unique molecules in a library), lower coverage, and lower confidence, which results in low-quality data and inaccurate results ([Figure 1](#)).




Figure 1. Comparison of sequencing results with high vs. low library conversion. The variant (orange) is lost in the library on the right with low conversion leading to low sensitivity. The light grey sequences and light orange variant (dot) on the left side indicate missing sequences and missing coverage.




Figure 2. Overview of study. Fresh-frozen normal tissue, tumor-derived FFPE tissue, and plasma cfDNA were extracted from 3 lung cancer subjects. The fresh-frozen normal and FFPE tissues were used for hybridization capture to identify tumor-associated variants. The results from that sequencing were used to design subject-specific xGen Custom Hyb Panels for use in targeted deep sequencing of the plasma cfDNA.

Here, we analyze matched archival lung cancer samples to show how IDT's NGS products enable confident and accurate variant identification in difficult FFPE and cfDNA samples (Figure 2). To demonstrate the identification of circulating tumor DNA (ctDNA) in a subject's sample, tumor-associated variants in matched FFPE and cfDNA samples are pinpointed in archived lung cancer trios.

RESULTS

Great research performance from low-quality FFPE samples

Matched FFPE-tumor, adjacent fresh-frozen normal, and plasma samples from 3 donors were sourced from a commercial biobank. DNA was extracted from these samples with the AnaPrep FFPE DNA Extraction Kit (PN: Z1322009, BioChain) and the cfPure® V2 Cell-Free DNA Extraction Kit (PN: K5011610-V2, BioChain). Standard quality control methods were used to assess the quality of the samples, including fluorometric quantification (Qubit™ dsDNA BR Assay Kit, Thermo Fisher Scientific), capillary electrophoresis (Bioanalyzer HS DNA chip, Agilent), or qPCR (KAPA hgDNA Quantification and QC Kit, Roche), depending on the sample (Table 1). Quality scores (Q scores) depict DNA quality as the ratio of 129 bp vs. 41 bp reads. An ideal Q score is 1, indicating equivalent amplification of both reads and, therefore, higher DNA integrity. The DNA Integrity Number (DIN) ranges from 1 to 10 where 1 is degraded DNA and 10 is intact DNA.

Table 1. Sample quality control.

	Fresh-frozen normal			FFPE tumor			cfDNA	
	Conc.* (ng/μl)	Q129/ Q41	DIN	Conc. (ng/μl)	Q129/ Q41	DIN	Conc. (ng/μl)	Bioanalyzer†
Trio 1	69.13	0.82	9.7	53.95	0.75	5.5	3.11	Minimal HMW DNA
Trio 2	37.38	1.15	7.2	202.5	0.76	5.9	2.33	Minimal HMW DNA
Trio 3	37.62	0.6	6.3	32.39	0.56	4.2	2.72	Minimal HMW DNA

* Conc. = concentration

† HMW = high molecular weight

Sequencing libraries were generated with 100 ng of DNA extracted from FFPE samples and adjacent fresh-frozen normal samples from all 3 donors. Regardless of input sample quality, the xGen cfDNA & FFPE DNA Library Prep Kit generated high-yield libraries (Figure 3). These libraries were captured in singleplex with a custom xGen cancer panel and sequenced. Picard was used to evaluate library preparation and hybrid capture performance including HS library size, duplicate rate, and coverage after standard start-stop deduplication (Figure 4). Since the goal of this study was to identify as many variants as possible, we chose to use start-stop deduplicated data. This approach sacrifices confidence in the veracity of the variants identified but can retain higher sensitivity. However, if the goal is to identify high-confidence, low-frequency variants, the libraries could be sequenced more deeply to reach the recommended duplication rates (>70%) for single read family error correction. In this study, higher coverage combined with high sensitivity was sufficient to identify tumor variants incorporated in subject-specific hybridization capture panels used to assess cfDNA for ctDNA.




Figure 3. The xGen cfDNA & FFPE DNA Library Prep Kit delivers high-yield and complex libraries from FFPE samples across a range of sample qualities. Libraries derived from fresh-frozen normal (FF) and FFPE-tumor samples were generated with 100 ng of input material and PCR amplified with 8 and 9 cycles, respectively. cfDNA libraries were generated from 25 ng of input and amplified with 8 PCR cycles. Library yield was measured with a Qubit™ fluorometer using the Qubit™ dsDNA BR Assay Kit (Thermo Fisher Scientific).




Figure 4. High-quality sequencing libraries from tumor and normal samples. Libraries derived from fresh-frozen normal and FFPE-tumor samples were generated with the xGen cfDNA & FFPE DNA Library Prep Kit from 100 ng of input material. Libraries were captured in singleplex with a custom 2.2 Mb xGen cancer panel. Libraries were pooled and sequenced on NextSeq™ 500 (Illumina) instrument. Reads were downsampled to 140 M reads per library and mapped using BWA (0.7.15). Libraries were then deduplicated based on start-stop position using Picard (2.18.9) or fgbio (0.7.0), as described in the [xGen cfDNA & FFPE DNA Library Prep Kit Analysis Guidelines](#). HS library size was calculated using Picard [3].

Variants, including single nucleotide polymorphisms (SNPs), insertion/deletions (indels), and mutations, were called from the matched fresh-frozen normal and FFPE-tumor samples using Vardict and Mutect2. Variants present in FFPE-tumor samples, but absent in matched fresh-frozen normal samples were defined as tumor-associated variants. In addition, germline variants present in these samples were identified (Table 2). This workflow identified approximately 250 variants per subject. The variants were targeted using xGen Custom Hyb Panels designed using IDT's design algorithm for 2X tiling.

Table 2. Variants identified in FFPE-tumor samples and sample-specific panel design.

Descriptions	Trio 1	Trio 2	Trio 3
SNPs in both Vardict & Mutect2 >1% AF*	25	34	45
Indels in both Vardict & Mutect2 >10% AF	4	38	12
Mutations overlapping <i>EGFR</i> , <i>KRAS</i> , <i>ERBB2</i> >1% AF	26	45	31
Germline indels >90% AF overlapping exons	6	8	5
Germline SNPs >90% AF overlapping exons	166	154	158
Total # of mutations	227	279	251
# of probes in BED file	276	363	305
Length of probe	27 kb	34 kb	30 kb

* AF = allele frequency

xGen cfDNA & FFPE DNA Library Prep Kit enables variant identification in cfDNA with confidence

High-yield libraries were generated with 25 ng of cfDNA from each of the trios (Figure 3). The libraries were captured with subject-matched custom xGen Custom Hyb Panels (IDT). Incorporation of unique dual indexes (UDIs) ensured accuracy and prevented sample misassignment. Despite the small size of these panels, we obtained high on-target rates and achieved a sequence depth sufficient to reach duplication rates of >80%, which is recommended for collapsed read analysis to enable error correction (Figure 5A). Collapsing reads uses unique molecular identifiers (UMIs) to remove sample-prep, library-prep, and sequencing errors, allowing accurate variant calling of ultra low-frequency variants. Mapped reads were used to generate collapsed single and combined read families, as outlined in the [xGen cfDNA & FFPE DNA Library Prep Kit Analysis Guidelines](#). The combination of the xGen cfDNA & FFPE DNA Library Prep Kit with xGen hybridization capture resulted in high conversion rates, complexity, and coverage for cfDNA (Figure 5B). Consequently, analysis of combined read family error-corrected coverage was able to identify low-frequency variants (Figure 6).




Figure 5. High complexity and coverage sequencing data from cfDNA. Libraries were generated with the xGen cfDNA & FFPE DNA Library Prep Kit from 25 ng of cfDNA material. Libraries were captured in singleplex with custom subject-specific xGen Custom Hyb Panels. Libraries were pooled and sequenced on a NextSeq™ 500 (Illumina) instrument. Reads were downsampled to 40 M reads per library and mapped using BWA (0.7.15). Libraries were then deduplicated based on start-stop position using Picard (2.18.9), or error-corrected with combined read families using fgbio (0.7.0), as described in the [xGen cfDNA & FFPE DNA Library Prep Kit Analysis Guidelines](#). (A) On-target rate was calculated using Picard percent selected bases. HS library size, and (B) coverage were also calculated using Picard [2].




Figure 6. The xGen cfDNA & FFPE DNA Library Prep Kit enables high sensitivity and specificity for ultra low-frequency variant identification of ctDNA. Libraries were generated according to the xGen cfDNA & FFPE DNA Library Prep Kit protocol using 25 ng matched cfDNA. Libraries were captured with subject-specific xGen Custom Hyb Panels. After sequencing, reads were mapped using BWA (0.7.15). Error correction with combined read families was performed as described in the [xGen cfDNA & FFPE DNA Library Prep Kit Analysis Guidelines](#). Finally, variants were called using VarDict (1.5.8); no filters were applied for the error-corrected xGen cfDNA & FFPE DNA Library Prep Kit data. **(A)** Allele fraction of each tumor-associated variant for each subject is shown. **(B)** Sensitivity to subject-specific biomarkers is shown, alongside near-perfect PPV, meaning there were no false positives. PPV = positive predictive value.

CONCLUSIONS AND FUTURE DIRECTIONS

Here, we present confident and accurate identification of low-frequency variants in matched tissue and cfDNA samples by combining IDT NGS products. Using an archived lung cancer trio for research, fresh-frozen normal tissue and tumor-derived FFPE samples were sequenced starting with the xGen cfDNA & FFPE DNA Library Prep Kit, which is optimized for low-input and degraded samples, and enriched using IDT xGen NGS Hybridization Capture. xGen Custom Hyb Panels are designed to target tumor-associated variants identified by hybridization capture for research. These subject-specific variants were identified with targeted deep sequencing of the subjects' plasma cfDNA and ctDNA variants. Use of the xGen cfDNA & FFPE DNA Library Prep Kit resulted in:

- High conversion rates resulting from novel ligase and highly modified adapters
- High-complexity libraries, which enable identification of variants at $\leq 1\%$ variant allele frequency (VAF)
- High yield and library complexity from severely degraded, FFPE samples
- Minimal errors using UMIs and minimized risk of sample misassignment using UDI primers
- Analysis of tumor-associated variants in trios using a single, streamlined workflow for cfDNA and FFPE

The technologies presented here aid researchers when examining cancer outcomes.

REFERENCES

1. Wang Z, Jensen MA, et al. (2016) **A practical guide to The Cancer Genome Atlas (TCGA)**. *Methods Mol Biol* 1418:111–141.
2. Institute B (2019) Picard Toolkit. Broad Institute, GitHub repository <http://broadinstitute.github.io/picard/>.



Your distributor in Switzerland

LubioScience GmbH
Baumackerstrasse 24
8050 Zürich
+41 (0)41 417 02 80

info@lubio.ch
www.lubio.ch

Technical support: applicationsupport@idtdna.com

For more than 30 years, IDT's innovative tools and solutions for genomics applications have been driving advances that inspire scientists to dream big and achieve their next breakthroughs. IDT develops, manufactures, and markets nucleic acid products that support the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. We have a global reach with personalized customer service.

> SEE WHAT MORE WE CAN DO FOR YOU AT WWW.IDTDNA.COM.

For Research Use Only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.

© 2022 Integrated DNA Technologies, Inc. All rights reserved. xGen is a trademark of Integrated DNA Technologies, Inc., and is registered in the USA. All other trademarks are the property of their respective owners. For specific trademark and licensing information, see www.idtdna.com/trademarks. Doc ID: RUO22-0675_001 04/22